Sulfonylurea derivatives in the light of evidence-based medicine and algorithms of diabetes mellitus type 2


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

The analyzed data from the large randomized placebo-controled clinical trials, conducted to evaluate the efficacy and safety of sulfoniluria in type 2 diabetes mellitus treatment, are observed in the review. Russian and foreign algorithms for the treatment of patients with type 2 diabetes mellitus are considered as well. The conclusion is that, among with innovative classes of glucose-lowering drugs, drugs from sulfonylureas group remain a strong position in the combination therapy stages, primarily due to the synergistic effect in combination with metformin. It is noted that unlike many other drugs from sulfonylureas group glimepiride is characterized by high compliance, which certainly contributes to the effectiveness of glucose-lowering therapy. In combination with metformin, glimepiride is one of the most effective and well-tolerated sulfonilurea, allowing to obtain an adequate glycemic control in patients who have not reached the treatment target on monotherapy.

Full Text

Restricted Access

About the authors

Tatiana Yulievna Demidova

Russian Medical Academy of Postgraduate Education

Email: t.y.demidova@gmail.com
MD, professor, professor of the Department of endocrinology

References

  1. DF Diabetes Atlas. Brussels, Belgium: International Diabetes Federation; 2014.
  2. Дедов И.И., Шестакова М.В., Аметов А.С., Анциферов М.Б., Галстян Г.Р., Майоров А.Ю., Мкртумян А.М., Петунина Н.А., Сухарева О.Ю. Инициация и интенсификация сахароснижающей терапии у больных сахарным диабетом 2 типа: обновление консенсуса совета экспертов Российской ассоциации эндокринологов (2015). Сахарный диабет. 2015;18(1):5-23. [Dedov I.I., Shestakova M.V. Ametov A.S., Antsiferov M.B., Galstyan G.R., Mayorov A.Yu., Mkrtumyan A.M., Petunina N.A. Sukhareva O.Yu. Initiation and intensification of antihyperglycemic therapy in patients with diabetes type 2: update of a consensus of Council of experts of the Russian Association of endocrinologists (2015). Diabetes Mellitus. 2015;18(1):5-23 (in Russian)]
  3. Dedov I., Shestakova M., Benedetti M.M., Simon D., Pakhomov I., Galstyan G. Prevalence of type 2 diabetes mellitus (T2DM) in the adult russian population (NATION study). Diabetes Res. Clin. Pract. 2016;115:90-5.
  4. Алгоритмы специализированной медицинской помощи больным сахарным диабетом. Под редакцией И.И. Дедова, М.В. Шестаковой (7-й выпуск). Сахарный диабет. 2015;18(1S):1-112. [Algorithms of specialized medical care for patients with diabetes. Edited by 1.1. Dedov, M.V. Shestakova (7th edition). Diabetes Mellitus. 2015; 18(1 S): 1 -112 (in Russian)]
  5. Inzucchi S.E., Bergenstal R.M., Buse J.B., Diamant М., Ferrannini Е., Nauck М., Peters A.L. , Tsapas А., Wender R,, Matthews D.R. Management of hyperglycaemia in type 2 diabetes, 2015: a patient-centred approach. Update to a position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia. 2015;58(3):429-42.
  6. Jonas D., Van Scoyoc E., Gerrald K., Wines R., Amick H., Triplette M., Runge T. Drug class review: newer diabetes medications, TZDs and combinations. Oregon Health & Science University. 2011 Feb.
  7. Scholz G.H., Schneider K., Knirsch W., Becker G. Efficacy and tolerability of glimepiride in daily practice. Clin. Drug Investig. 2001;21(9):597-604.
  8. Bugos C., Austin M., Atherton T., Viereck C. Long-term treatment of type 2 diabetes mellitus with glimepiride is weight neutral: a meta-analysis. Diabetes Res. Clin. Pract. 2000;50(Suppl. 1):S47.
  9. Holstein A., Plaschke A., Egberts E.H. Lower incidence of severe hypoglycaemia in patients with type 2 diabetes treated with glimepiride versus glibenclamide, Diabetes. Metab. Res. Rev. 2001;17(6):467-73.
  10. Dills D.G., Schneider J., Group G.R. Clinical evaluation of glimepiride versus glyburide in NIDDM in a double-blind comparative study. Horm. Metab. Res. 1996;28(9):426-9.
  11. Ashcroft F.M., Gribble F.M. ATP-sensitive K+ channels and insulin secretion: their role in health and disease. Diabetologia. 1999;42(8):903-19.
  12. Kramer W., Müller G., Geisen K. Characterization of the molecular mode of action of the sulfonylurea, glimepiride, at ß-cells. Horm. Metab. Res. 1996;28(9):464-8.
  13. Инструкция по медицинскому применению препарата Амарил. [Instructions for medical use of the drug Amaryl (in Russian)]
  14. Korytkowski M., Thomas A., Reid L., Tedesco M.B., Gooding W.E., Gerich J. Glimepiride improves both first and second phases of insulin secretion in type 2 diabetes. Diabetes Care. 2002;25(9):1607-1 1.
  15. Massi-Benedetti M., Herz M., Pfeiffer C. The effects of acute exercise on metabolic control in type II diabetic patients treated with glimepiride or glibenclamide. Horm. Metab. Res. 1996;28(9):451-5.
  16. Müller G., Hartz D., Pünter J., Okonomopulos R., Kramer W. Differential interaction of glimepiride and glibenclamide with the β-cell sulfonylurea receptor I. Binding characteristics. Biochim. Biophys. Acta (BBA)-Biomembranes. 1994;1 191(2):267-77.
  17. Klepzig H., Kober G., Matter C., Luus H., Schneider H., Boedeker K.H., Kiowski W., Amann F.W., Gruber D., Harris S., Burger W. Sulfonylureas and ischaemic preconditioning; a double-blind, placebo-controlled evaluation of glimepiride and glibenclamide. Eur. Heart J. 1999;20(6):439-46.
  18. El-Reyani N.E., Bozdogan O., Baczká I., Leprán I., Papp J.G. Comparison of the efficacy of glibenclamide and glimepiride in reperfusion-induced arrhythmias in rats. Eur. J. Pharmacol. 1999;365(2-3):187-92.
  19. Xu D., Zhao S.P., Huang Q.X., Du W., Liu Y.H., Liu L., Xie X.M. Effects of glimepiride on metabolic parameters and cardiovascular risk factors in patients with newly diagnosed type 2 diabetes mellitus. Diabetes Res. Clin. Pract. Elsevier Ireland Ltd. 2010;88(1):71-5.
  20. Howard B.V. Lipoprotein metabolism in diabetes mellitus. J. Lipid Res. 1987;28(6):613-28.
  21. Sharma S.C. Platelet adhesiveness, plasma fibrinogen, and fibrinolytic activity in juvenile-onset and maturity-onset diabetes mellitus. J. Clin. Pathol. 1981;34(5):501-3.
  22. Yukio O., Yutaka Y., Shoji K. Effects of oral hypoglycaemic agents on platelet functions. Biochem. Pharmacol. 1992;44(4):687-91.
  23. Siluk D., Kaliszan R., Haber P., Petrusewicz J., Brzozowski Z., Sut G. Antiaggregatory activity of hypoglycaemic sulphonylureas. Diabetologia. 2002;45(7):1034-7.
  24. Hink U., Li H., Mollnau H., Oelze M., Matheis E., Hartmann M., Skatchkov M., Thaiss F., Stahl R.A., Warnholtz A., Meinertz T., Griendling K., Harrison D.G., Forstermann U., Munzel T. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 2001;88(2):e14-e22.
  25. Schade D.S., Jovanovic L., Schneider J. A placebo-controlled randomized study of glimepiride in patients with type 2 diabetes mellitus for whom diet therapy is unsuccessful. J. Clin. Pharmacol. 1998;38(7):636-41.
  26. Ametov A.S., Abaeva F.T. Efficacy and safety of glimepiride as initial treatment in Russian patients with type 2 diabetes mellitus. Diabetes Mellit. 2013;16(4):95.
  27. Guo X.H., Lv X.F., Han P., Zhang X.Z., Yang H.Z., Duan W.R., Gao Y. Efficacy and safety of glimepiride as initial treatment in Chinese patients with type 2 diabetes mellitus. Curr. Med. Res. Opin. 2013;29(3):169-74.
  28. Rosenstock J., Samols E., Muchmore D.B., Schneider J. Glimepiride, a new once-daily sulfonylurea: a double-blind placebo-controlled study of NIDDM patients. Diabetes Care. 1996;19(11):1194-9.
  29. Scholz G.H. et al. Efficacy and tolerability of glimepiride in daily practice: A non-interventional observational cohort study. Clin. Drug Investig. 2001;21(9):597-604.
  30. Weitgasser R., Lechleitner M., Luger A., Klingler A. Effects of glimepiride on HbA1c and body weight in type 2 diabetes: results of a 1.5-year follow-up study. Diabetes Res. Clin. Pract. 2003;61(1):13-9.
  31. Martin S., Kolb H., Beuth J., van Leendert R., Schneider B., Scherbaum W.A. Change in patients' body weight after 12 months of treatment with glimepiride or glibenclamide in type 2 diabetes: a multicentre retrolective cohort study. Diabetologia. 2003;46(12):1611-7.
  32. Rosskamp R., Wernicke-Panten K., Draeger E. Clinical profile of the novel sulphonylurea glimepiride. Diabetes Res. Clin. Pract. 1996;31(Suppl.):S33-42.
  33. Charpentier G., Fleury F., Kabir M., Vaur L., Halimi S. Improved glycaemic control by addition of glimepiride to metformin monotherapy in type 2 diabetic patients. Diabet. Med. 2001;18(10):828-34.
  34. Pareek A., Chandurkar N.B., Salkar H.R., Borkar M.S., Tiwari D. Evaluation of efficacy and tolerability of glimepiride and metformin combination: A multicentric study in patients with type-2 diabetes mellitus, uncontrolled on monotherapy with sulfonylurea or metformin. Am. J. Ther. 2013;20(1):41-7.
  35. Melikian C., White T.J., Vanderplas A., Dezii C.M., Chang E. Adherence to oral antidiabetic therapy in a managed care organization: A comparison of monotherapy, combination therapy, and fixed-dose combination therapy. Clin. Ther. 2002;24(3):460-7.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies